Larimar Therapeutics (LRMR) Net Cash Flow (2016 - 2020)
Historic Net Cash Flow for Larimar Therapeutics (LRMR) over the last 8 years, with Q4 2020 value amounting to -$33.2 million.
- Larimar Therapeutics' Net Cash Flow fell 63590.77% to -$33.2 million in Q4 2020 from the same period last year, while for Dec 2020 it was $68.5 million, marking a year-over-year increase of 212178.92%. This contributed to the annual value of $5.7 million for FY2024, which is 496837.61% up from last year.
- Larimar Therapeutics' Net Cash Flow amounted to -$33.2 million in Q4 2020, which was down 63590.77% from -$11.4 million recorded in Q3 2020.
- Larimar Therapeutics' Net Cash Flow's 5-year high stood at $113.1 million during Q2 2020, with a 5-year trough of -$33.2 million in Q4 2020.
- Its 5-year average for Net Cash Flow is $3.9 million, with a median of $1.5 million in 2017.
- Over the last 5 years, Larimar Therapeutics' Net Cash Flow had its largest YoY gain of 122139.94% in 2020, and its largest YoY loss of 63590.77% in 2020.
- Larimar Therapeutics' Net Cash Flow (Quarter) stood at $7.5 million in 2016, then skyrocketed by 188.13% to $21.6 million in 2017, then crashed by 80.59% to $4.2 million in 2018, then plummeted by 207.54% to -$4.5 million in 2019, then plummeted by 635.91% to -$33.2 million in 2020.
- Its Net Cash Flow was -$33.2 million in Q4 2020, compared to -$11.4 million in Q3 2020 and $113.1 million in Q2 2020.